*Purpose: The current American Society of Transplantation-ID guidelines recommend the MMR and VZV serologic screening pre transplantation for of all persons born after 1956. MMR serologic screening is not protocol driven at our institution, but varicella is. The objective of the study was to determine the adequacy of MMR/VZV screening at our institution. The secondary aim was to determine the frequency of vaccination among those who were seronegative.

*Methods: A retrospective review of all kidney transplant candidates at Mayo Clinic Florida between 1/1/2015 and 12/31/2017 was conducted. The project was IRB approved. If the kidney transplant candidate was born after 1956, their demographics, immune status, serologic markers for MMR and varicella, and vaccine administration were obtained from medical records. Descriptive statistics including serologies and vaccine information were reported as frequency and percentage.

*Results: Measles, mumps, rubella and varicella serologies were tested and 100 (35.1%), 3 (1.1%), 119 (42%) and 248 (87.6%) of the 283 kidney transplant candidates respectively. Among the 35 MMR seronegative candidates, MMR vaccine was given to 11 (31.4%). Nine (64.3%) candidates received either varicella or Zostavax among the 14 seronegative candidates. None of the immunocompromised patients who were seronegative received any live virus vaccine.

*Conclusions: • 1) MMR serologic screening pre transplantation was low • 2) Varicella screening had higher rates since that was protocol driven • 3) No immunocompromised host was immunized • 4) MMR serologic screening needs to be protocol driven

« Back to 2019 American Transplant Congress